Tag - Mati Therapeutics

Executive Moves

Mati promotes Chris Muller to COO

Closely-held Mati Therapeutics named Chris Muller as COO, effective immediately. Most recently Mati’s CCO, Mr. Muller’s expanded responsibilities include overseeing all operating activities; and preparing for and...

September 28, 2023

Developments

Mati completes manufacturing facility; prepares for Phase 3 nepafenac trial

Closely-held Mati Therapeutics completed a dedicated manufacturing facility for products formulated using the company’s Evolute sustained ocular drug delivery platform. Mati expects that the 10,000-square-foot facility...

September 15, 2023

Developments

Mati Therapeutics expands IP portfolio to 114 patents in 19 patent families

Closely-held Mati Therapeutics’ international patent portfolio has grown to 114 issued patents, including a recently granted U.S. patent, which covers a drug delivery system for administering an ophthalmic drug through...

October 24, 2018

Developments

Mati Therapeutics posts positive interim Phase 2 nepafenac results in cataract surgery pain reduction

Closely-held Mati Therapeutics reported encouraging results from a planned interim analysis of an ongoing Phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s Evolute sustained...

September 10, 2018

Feature

Mati Therapeutics isn’t your traditional biotech startup

By Len Zehr Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to eye...

June 10, 2014

Tag - Mati Therapeutics

Mati promotes Chris Muller to COO

Mati completes manufacturing facility; prepares for Phase 3 nepafenac trial

Mati Therapeutics expands IP portfolio to 114 patents in 19 patent families

Mati Therapeutics posts positive interim Phase 2 nepafenac results in cataract surgery pain reduction

Mati Therapeutics isn’t your traditional biotech startup

General

More